NasdaqGM:IRONBiotechs
Why Disc Medicine (IRON) Is Up 7.7% After Advancing Key Late-Stage Anemia Candidates
Disc Medicine has launched a U.S. expanded access program for bitopertin in erythropoietic and X-linked protoporphyria and presented updated Phase 2 RALLY-MF data for DISC-0974 in myelofibrosis-related anemia, showing clinically meaningful improvements in hemoglobin, transfusion needs, and fatigue with a generally well-tolerated safety profile.
Together, these updates underscore Disc Medicine’s push to advance multiple late-stage hematology candidates, with DISC-0974’s broad responses across...